You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for 5,7-Dichlorokynurenic acid
5,7-Dichlorokynurenic acid is a potent antagonist at the glycine site of the NMDA receptor (Ki = 79 nM vs. [3H]-glycine).
Sodium Salt also available.
Compound Libraries for 5,7-Dichlorokynurenic acid
Technical Data for 5,7-Dichlorokynurenic acid
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for 5,7-Dichlorokynurenic acid
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for 5,7-Dichlorokynurenic acid
The following data is based on the product molecular weight 258.06. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.88 mL||19.38 mL||38.75 mL|
|5 mM||0.78 mL||3.88 mL||7.75 mL|
|10 mM||0.39 mL||1.94 mL||3.88 mL|
|50 mM||0.08 mL||0.39 mL||0.78 mL|
Product Datasheets for 5,7-Dichlorokynurenic acid
References for 5,7-Dichlorokynurenic acid
References are publications that support the biological activity of the product.
Baron et al (1990) Activity of 5,7-dichlorokynurenic acid. A potent antagonist at the NMDA receptor-associated glycine binding site. Mol.Pharmacol. 38 554 PMID: 2172769
Moore et al (1990) Substituted kynurenic acid derivatives. Potent and selective antagonists at the glycine site on the NMDA receptor. Eur.Fed.Med.Chem. (under auspices of IUPAC) XIth I 29
If you know of a relevant reference for 5,7-Dichlorokynurenic acid, please let us know.
View Related Products by Product Action
Keywords: 5,7-Dichlorokynurenic acid, 5,7-Dichlorokynurenic acid supplier, Potent, NMDA, antagonists, glycine, site, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, 0286, Tocris Bioscience
4 Citations for 5,7-Dichlorokynurenic acid
Citations are publications that use Tocris products. Selected citations for 5,7-Dichlorokynurenic acid include:
Adamsky et al (2018) Astrocytic Activation Generates De Novo Neuronal Potentiation and Memory Enhancement. Cell 174 59 PMID: 29804835
Kenny et al (2009) The integrity of the glycine co-agonist binding site of N-MthD.-aspartate receptors is a functional quality control checkpoint for cell surface delivery. J Biol Chem 284 324 PMID: 18990687
Astorga et al (2015) An excitatory GABA loop operating in vivo. Front Cell Neurosci 9 275 PMID: 26236197
Stevens et al (2010) Light-evoked NMDA receptor-mediated currents are reduced by blocking D-serine synthesis in the salamander retina. Cell Commun Signal 21 239 PMID: 20101193
Do you know of a great paper that uses 5,7-Dichlorokynurenic acid from Tocris? Please let us know.
Reviews for 5,7-Dichlorokynurenic acid
There are currently no reviews for this product. Be the first to review 5,7-Dichlorokynurenic acid and earn rewards!
Have you used 5,7-Dichlorokynurenic acid?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.